Section Arrow
BBIO.NASDAQ
- BridgeBio Pharma
Quotes are at least 15-min delayed:2025/06/01 02:25 EDT
Last
 34.25
+0.88 (+2.64%)
Day High 
34.73 
Prev. Close
33.37 
1-M High
39.54 
Volume 
2.97M 
Bid
32.51
Ask
37
Day Low
32.37 
Open
33.09 
1-M Low
31.77 
Market Cap 
6.34B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 33.29 
20-SMA 34.62 
50-SMA 34.53 
52-W High 39.54 
52-W Low 21.62 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.56/-2.08
Enterprise Value
8.06B
Balance Sheet
Book Value Per Share
-8.68
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.30M
Operating Revenue Per Share
0.05
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed:2025/06/01 02:25 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.